Costa Rica exports buses for the first time

first_imgKorean company Daewoo Bus Costa Rica Co. this week is sending the first six buses built in the country to El Salvador. That nation bought a total of 12 buses at a cost of $2 million. The other six will be shipped in January.Last year, Costa Rica exported $280 million worth of auto parts, but this is the first time the country exports entire vehicles.The company also is working with Costa Rica’s Foreign Trade Promotion Office to involve local companies in the production business.The Daewoo plant in Santa Ana, southwest of the capital, has a production capacity of some 300 units per year. Daewoo also is the leading brand of buses in the country, with nearly 36 percent of the local market.“This company is an example of how foreign direct investment contributes to the dynamism in the economy, the development of local suppliers and the transfer of technology and knowledge,” Foreign Trade Minister Anabel González said during a ceremony at the company’s facilities on Monday. Facebook Comments No related posts.last_img read more

Read More →

Biosimilar competition may offer hope for cheaper better psoriasis treatments in the

first_imgJun 20 2018A new study by iData Research estimates that there are nearly 150,000 new cases of psoriasis (PsO) every year in the United States, affecting 2.2% of the population. Approximately 80% of those affected have mild-to-moderate psoriasis, while 20% have moderate-to-severe psoriasis, which is often treated with immunology drugs. These drugs command a high price, but there may be hope for better options in the future.People with psoriasis suffer from the overproduction of skin cells, which causes the redness and inflammation typically found on elbows, knees, or the scalp. The disease is usually associated with other serious health conditions, often involving the immune system. Crohn’s disease and ulcerative colitis are some examples, both of which can be up to 7 times more prevalent in psoriasis patients.Psoriasis patients have a number of treatment options, ranging from non-steroidal anti-inflammatory drugs for initial treatment to biologics, which are more often used in moderate-to-severe forms of the disease. The PsO market is dominated by drugs such as Humira®, Enbrel®, Remicade® and Stelara®, but more competition is coming soon from biosimilars as patents begin to expire.Related StoriesComplement system shown to remove dead cells in retinitis pigmentosa, contradicting previous researchArtificial DNA can help release active ingredients from drugs in sequenceAMSBIO offers new, best-in-class CAR-T cell range for research and immunotherapyResearch by iData shows that the average annual drug cost per patient in the U.S. is over $60,000. Stelara® and Humira® are the most-prescribed immunology drugs for psoriasis treatment, due to their high efficacy, and are clearly benefiting from the lack of competition, which enables them to sell at these prices.The U.S. psoriasis market is valued at almost $5 billion, growing year over year. According to this latest study, the PsO market is expected to reach $6.33 billion by 2023. This market growth is driven by the high cost of the biologics, unmet needs in the psoriasis space, and the efficacy of anti-TNF biologics. “Despite this trend, biologics are seeing a lower growth rate as a direct result of competition from the immunology biosimilar market, which will experience a compound annual growth rate exceeding 30% over the forecast period,” says Dr. Kamran Zamanian, President and CEO of iData Research.AbbVie’s Humira® is expected to remain exempt from biosimilar competition in the U.S. until 2023, due to strong ancillary patents and ongoing litigation with other pharmaceutical companies. The entrance of biosimilars will benefit patients both directly, by providing them with lower-cost treatment alternatives, and indirectly, through applying downward pressure on the cost of the originator biologics.Source: https://idataresearch.com/last_img read more

Read More →